Expression of Plasma miRNA-133a is Significantly Lower in Acute Coronary Syndrome (ACS) than in Healthy/Non-ACS Subjects
Abstract
BACKGROUND: The current biomarker diagnostic modality for acute coronary syndrome (ACS), cardiac troponin, has several limitations. Emerging studies showed that micro-RNA (miR)-133a was released from infarcted heart to circulation, yet the diagnostic value of miR-133a in ACS demonstrated a conflicting result. Therefore, this study was conducted to investigate the potency of plasma miR-133a as a biomarker candidate of ACS.
METHODS: This was a case-controlled study, involving ACS and control subjects. The sociodemographic and clinical characteristics were assessed through medical records. A final of 39 ACS and 31 control subjects (consist of healthy and non-ACS subjects) passed the selection procedure by demonstrating a high purity of RNA. miR-133a from ACS and control subjects were detected by quantitative polymerase chain reaction (qPCR). Expression of miR-133a was evaluated for sensitivity and specificity as an ACS biomarker diagnostic using the receiver operating characteristic (ROC) curve.
RESULTS: Plasma miR-133a expression was stably found in ACS subjects. The plasma miR-133a level was lower in ACS than in control subjects. miR-133a effectively distinguished ACS subjects from healthy subjects (AUC=0.911) and exhibited high diagnostic performance, with a sensitivity of 87.1% and specificity of 100% at a cut-off value of 44.035. In an extended model including both control subjects (healthy and non-ACS with comorbid conditions), miR-133a maintained diagnostic significance (AUC=0.874), showing sensitivity of 76.9% and specificity of 100% at a cut-off value of 11.69.
CONCLUSION: Plasma miR-133a is significantly lower and effectively distinguishes ACS patients from both healthy individuals and non-ACS individuals with comorbid, with a cut-off value of 11.69. Therefore, plasma miR-133a is suggested to be a good candidate for diagnostic biomarkers of ACS.
KEYWORDS: circulating miRNA, miRNA-133a, acute coronary syndrome, diagnostic biomarker
Full Text:
PDFReferences
Juzar DA, Muzakkir AF, Ilhami YR, Taufiq N, Astiawati T, Junior IM, et al. Management of acute coronary syndrome in Indonesia: Insight from one ACS multicenter registry. Indones J Cardiol. 2022; 43(2): 45-55, CrossRef.
Salari N, Morddarvanjoghi F, Abdolmaleki A, Rasoulpoor S, Khaleghi AA, Hezarkhani LA, et al. The global prevalence of myocardial infarction: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2023; 23(1): 206, CrossRef.
Uli RE, Satyana RPU, Zomer E, Magliano D, Liew D, Ademi Z. Health and productivity burden of coronary heart disease in the working Indonesian population using life-table modelling. BMJ Open. 2020; 10(9): e039221, CrossRef.
Faramand Z, Helman S, Ahmad A, Martin-Gill C, Callaway C, Saba S, et al. Performance and limitations of automated ECG interpretation statements in patients with suspected acute coronary syndrome. J Electrocardiol. 2021; 69S: 45-50, CrossRef.
Suzuki K, Komukai K, Nakata K, Kang R, Oi Y, Muto E, et al. The usefulness and limitations of point-of-care cardiac troponin measurement in the emergency department. Intern Medi. 2018; 57(12): 1673-80, CrossRef.
Park KC, Gaze DC, Collinson PO, Marber MS. Cardiac troponins: From myocardial infarction to chronic disease. Cardiovasc Res. 2017; 113(14): 1708-18, CrossRef.
Meiliana A, Wijaya A. The Changing face of atherosclerosis. Indones Biomed J. 2023; 15(3): 194-221, CrossRef.
Tanase DM, Gosav EM, Costea CF, Ciocoiu M, Lacatusu CM, Maranduca MA, et al. The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD). J Diabetes Res. 2020; 2020: 3920196, CrossRef.
Califf RM. Biomarker definitions and their applications. Exp Biol Med. 2018; 243(3): 213-21, CrossRef.
Liebetrau C, Möllmann H, Dörr O, Szardien S, Troidl C, Willmer M, et al. Release kinetics of circulating muscle-enriched microRNAs in patients undergoing transcoronary ablation of septal hypertrophy. J Am Coll Cardiol. 2013; 62(11): 992-8, CrossRef.
Li S, Lee C, Song J, Lu C, Liu J, Cui Y, et al. Circulating microRNAs as potential biomarkers for coronary plaque rupture. Oncotarget. 2017; 8(29): 48145-56, CrossRef.
Meiliana A, Wijaya A. MicroRNAs in lipid metabolism and atherosclerosis. Indones Biomed J. 2014; 6(1): 3-16, CrossRef.
Zhao Y, Song X, Ma Y, Liu X, Peng Y. Circulating mir-483-5p as a novel diagnostic biomarker for acute coronary syndrome and its predictive value for the clinical outcome after PCI. BMC Cardiovasc Disord. 2023; 23(1): 360, CrossRef.
Zhu H, Liang H, Gao Z, Zhang X, He Q, He C, et al. MiR-483-5p downregulation alleviates ox-LDL induced endothelial cell injury in atherosclerosis. BMC Cardiovasc Disord. 2023; 23(1): 521, CrossRef.
Zhang H, Zhang Z, Liu Z, Mu G, Xie Q, Zhou S, et al. Circulating miR-320a-3p and miR-483-5p level associated with pharmacokinetic-pharmacodynamic profiles of rivaroxaban. Hum Genomics. 2022; 16(1): 72, CrossRef.
Kuwabara Y, Ono K, Horie T, Nishi H, Nagao K, Kinoshita M, et al. Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage. Circ Cardiovasc Genet. 2011; 4(4): 446-54, CrossRef.
Dan-Nwafor CC, Ogbonna U, Onyiah P, Gidado S, Adebobola B, Nguku P, et al. A cholera outbreak in a rural north central Nigerian community: An unmatched case-control study. BMC Public Health. 2019; 19(1): 112, CrossRef.
Le MN, Nguyen TA. Innovative microRNA quantification by qPCR. Mol Ther Nucleic Acids. 2023; 31: 628-30, CrossRef.
Altaf A, Shah H, Salahuddin M. Gender based differences in clinical and angiographic characteristics and outcomes of acute coronary syndrome (ACS) in Asian population. Pak J Med Sci. 2019; 35(5): 1349-54, CrossRef.
Pagidipati NJ, Peterson ED. Acute coronary syndromes in women and men. Nat Rev Cardiol. 2016; 13(8): 471-80, CrossRef.
Winzer EB, Woitek F, Linke A. Physical activity in the prevention and treatment of coronary artery disease. J Am Heart Assoc. 2018; 7(4): e007725, CrossRef.
Duran AT, Ewing Garber C, Cornelius T, Schwartz JE, Diaz KM. Patterns of sedentary behavior in the first month after acute coronary syndrome. J Am Heart Assoc. 2019; 8(15): e011585, CrossRef.
Anthony N, Hassan A, Ghani U, Rahim O, Ghulam M, James N, et al. Age-related patterns of symptoms and risk factors in acute coronary syndrome (ACS): A study based on cardiology patients' records at Rehman Medical Institute, Peshawar. Cureus. 2024; 16(4): e58426, CrossRef.
Indah AA, Ramadhan P V, Pratama V. Acute coronary syndrome in well trained young adult: A rare cases. Cardiovasc Cardiometabol J. 2020; 1(2): 69-76, CrossRef.
Lakew BA, Bekele DM, Alemu Kassa W, Dugassa Tolera B. Suboptimal knowledge and care of patients with acute coronary syndrome among nurses working in selected hospitals in Addis Ababa, Ethiopia 2021. Vasc Health Risk Manag. 2023; 19: 637-49, CrossRef.
Al-Zakwani I, M Mabry R, Zubaid M, Alsheikh-Ali AA, Almahmeed W, Shehab A, et al. Association between education and major adverse cardiac events among patients with acute coronary syndrome in the Arabian Gulf. BMJ Glob Health. 2019; 4(1): e001278, CrossRef.
Lauder L, Mahfoud F, Azizi M, Bhatt DL, Ewen S, Kario K, et al. Hypertension management in patients with cardiovascular comorbidities. 2023; 44(23): 2066-77, CrossRef.
Keller T, Zeller T, Peetz D, Tzikas S, Roth A, Czyz E, et al. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med. 2009; 361(9): 868-77, CrossRef.
Yang G, Yao Y, Du Y, Huang J. Cardiac troponin had limited diagnostic value for acute myocardial infarction in renal insufficiency: A meta-Analysis. Biomark Med. 2020; 14(6): 481-93, CrossRef.
Pikir BS, Andrianto, Suryawan IGR, Hermawan HO, Kartikasari DP, Harsoyo PM. microRNA-1 induces transdifferentiation of peripheral blood CD34+ cells into cardiomyocytes-like cells. Indones Biomed J. 2022; 14(3): 269-75, CrossRef.
Gidï O, Van Der Brug M, Jenny¨ohman JJ, Gilje P, Bj¨ B, Olde B, et al. Platelets activated during myocardial infarction release functional miRNA, which can be taken up by endothelial cells and regulate ICAM1 expression. Blood. 2013; 121(19): 3908-17, S1-26, CrossRef.
Xiao Y, Zhao J, Tuazon JP, Borlongan C V, Yu G. MicroRNA-133a and myocardial infarction. Cell Transplant. 2019; 28(7): 831-8, CrossRef.
Li A ying, Yang Q, Yang K. miR-133a mediates the hypoxia-induced apoptosis by inhibiting TAGLN2 expression in cardiac myocytes. Mol Cell Biochem. 2015; 400(1-2): 173-81, CrossRef.
He B, Xiao J, Ren AJ, Zhang YF, Zhang H, Chen M, et al. Role of miR-1 and miR-133a in myocardial ischemic postconditioning. J Biomed Sci. 2011; 18(1): 22, CrossRef.
Boštjančič E, Brandner T, Zidar N, Glavač D, Štajer D. Down-regulation of miR-133a/b in patients with myocardial infarction correlates with the presence of ventricular fibrillation. Biomed Pharmacother. 2018: 99: 65-71, CrossRef.
Wen P, Song D, Ye H, Wu X, Jiang L, Tang B, et al. Circulating MiR-133a as a biomarker predicts cardiac hypertrophy in chronic hemodialysis patients. PLoS One. 2014; 9(10): e103079, CrossRef.
Duisters RF, Tijsen AJ, Schroen B, Leenders JJ, Lentink V, Van Der Made I, et al. MiR-133 and miR-30 regulate connective tissue growth factor: Implications for a role of micrornas in myocardial matrix remodeling. Circ Res. 2009; 104(2): 170-8, CrossRef.
Wexler Y, Nussinovitch U. The diagnostic value of Mir-133a in ST elevation and non-ST elevation myocardial infarction: A meta-analysis. Cells. 2020; 9(4): 793, CrossRef.
Liu G, Niu X, Meng X, Zhang Z. Sensitive miRNA markers for the detection and management of NSTEMI acute myocardial infarction patients. J Thorac Dis. 2018; 10(6): 3206-15, CrossRef.
Peng L, Chun-guang Q, Bei-fang L, Xue-zhi D, Zi-hao W, Yun-fu L, et al. Clinical impact of circulating miR-133, miR-1291 and miR-663b in plasma of patients with acute myocardial infarction. Diagn Pathol. 2014; 9: 89. doi: 10.1186/1746-1596-9-89, CrossRef.
DOI: https://doi.org/10.18585/inabj.v16i5.3243
Copyright (c) 2024 The Prodia Education and Research Institute
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Indexed by:
The Prodia Education and Research Institute
